Stephanie S O'Malley1, Ran Wu2, Susan T Mayne3, Peter I Jatlow4. 1. Department of Psychiatry, Yale School of Medicine, New Haven, CT; Yale Comprehensive Cancer Center, New Haven, CT; stephanie.omalley@yale.edu. 2. Department of Psychiatry, Yale School of Medicine, New Haven, CT; 3. Yale Comprehensive Cancer Center, New Haven, CT; Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT; 4. Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT.
Abstract
INTRODUCTION: Lower concentrations of serum bilirubin, an endogenous antioxidant, have been associated with risk of many smoking-related diseases, including lung cancer and cardiovascular disease, and current smokers are reported to have lower bilirubin levels than nonsmokers and past smokers. This study evaluates the effects of smoking cessation on bilirubin levels. METHODS: In a secondary analysis of a 6-week placebo-controlled trial of naltrexone for smoking cessation, indirect and total bilirubin concentrations were evaluated at baseline and following smoking cessation. Individuals who were continuously abstinent for 6 weeks (n = 155) were compared to those who were not (n = 193). Participants reported smoking ≥ 20 cigarettes daily at baseline and received smoking cessation counseling, 21 mg nicotine patch daily, and either placebo or 1 of 3 doses of naltrexone (25, 50, or 100mg) for 6 weeks. Change in indirect and total bilirubin following the quit date was measured at Weeks 1, 4, and 6 compared to baseline. RESULTS: Individuals who were continuously abstinent from smoking, independent of naltrexone condition, showed a significantly greater mean increase in indirect (~unconjugated) bilirubin (0.06 mg/dl, SD = 0.165) compared to those who did not (mean = 0.02, SD = 0.148, p = .015). Similar results were obtained for total bilirubin (p = .037). CONCLUSIONS:Smoking cessation is followed by increases in bilirubin concentration that have been associated with lower risk of lung cancer and cardiovascular disease.
RCT Entities:
INTRODUCTION: Lower concentrations of serum bilirubin, an endogenous antioxidant, have been associated with risk of many smoking-related diseases, including lung cancer and cardiovascular disease, and current smokers are reported to have lower bilirubin levels than nonsmokers and past smokers. This study evaluates the effects of smoking cessation on bilirubin levels. METHODS: In a secondary analysis of a 6-week placebo-controlled trial of naltrexone for smoking cessation, indirect and total bilirubin concentrations were evaluated at baseline and following smoking cessation. Individuals who were continuously abstinent for 6 weeks (n = 155) were compared to those who were not (n = 193). Participants reported smoking ≥ 20 cigarettes daily at baseline and received smoking cessation counseling, 21 mg nicotine patch daily, and either placebo or 1 of 3 doses of naltrexone (25, 50, or 100mg) for 6 weeks. Change in indirect and total bilirubin following the quit date was measured at Weeks 1, 4, and 6 compared to baseline. RESULTS: Individuals who were continuously abstinent from smoking, independent of naltrexone condition, showed a significantly greater mean increase in indirect (~unconjugated) bilirubin (0.06 mg/dl, SD = 0.165) compared to those who did not (mean = 0.02, SD = 0.148, p = .015). Similar results were obtained for total bilirubin (p = .037). CONCLUSIONS: Smoking cessation is followed by increases in bilirubin concentration that have been associated with lower risk of lung cancer and cardiovascular disease.
Authors: Stephanie S O'Malley; Judith L Cooney; Suchitra Krishnan-Sarin; Joel A Dubin; Sherry A McKee; Ned L Cooney; Amy Blakeslee; Boris Meandzija; Denise Romano-Dahlgard; Ran Wu; Robert Makuch; Peter Jatlow Journal: Arch Intern Med Date: 2006-03-27
Authors: Jessica M van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron H N van Schaik; Maja J A de Jonge; André S Th Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong Journal: J Clin Oncol Date: 2007-06-11 Impact factor: 44.544
Authors: Fangyi Gu; Andriy Derkach; Neal D Freedman; Maria Teresa Landi; Demetrius Albanes; Stephanie J Weinstein; Alison M Mondul; Charles E Matthews; Kristin A Guertin; Qian Xiao; Wei Zheng; Xiao-Ou Shu; Joshua N Sampson; Steven C Moore; Neil E Caporaso Journal: Int J Epidemiol Date: 2015-12-31 Impact factor: 7.196
Authors: Krysten W Bold; Benjamin A Toll; Brenda Cartmel; Bennie B Ford; Alana M Rojewski; Ralitza Gueorguieva; Stephanie S O'Malley; Lisa M Fucito Journal: J Smok Cessat Date: 2017-12-11
Authors: Setor K Kunutsor; Lyanne M Kieneker; Stephen Burgess; Stephan J L Bakker; Robin P F Dullaart Journal: J Am Heart Assoc Date: 2017-11-13 Impact factor: 5.501